The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Influence of pharmaceutical care on health outcomes in patients with Type 2 diabetes mellitus
Open accessAbstract
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Pharmaceutical care programmes delivered by pharmacists are known to improve quality of care for both ambulatory and hospitalized patients with a variety of chronic and acute conditions. • Reduction of HbA 1c and normalization of blood pressure are key targets for diabetes care programmes, since they are key to reducing diabetes complications. • Good knowledge about disease, medications, diet and exercise requirements can improve the effectiveness of self‐management of diabetes. WHAT THIS STUDY ADDS • In a randomized, controlled clinical trial, a comprehensive pharmaceutical care programme (consisting of patient education and advice on medication adherence, metabolic control and life style) delivered by a clinical pharmacist over a 12‐month period, significantly improved glycaemic control and health‐related quality of life in Type 2 diabetes patients attending a military hospital outpatient clinic in the United Arab Emirates (UAE). • A significant reduction in HbA 1c was important in the reduction of the 10‐year coronary heart disease risk scores (by British National Formulary and Framingham methods) seen in patients who received the present care programme. • The outcomes of this study advocate an increased role for clinical pharmacists in the healthcare system in the UAE. AIMS To examine the influence of a pharmaceutical care programme on disease control and health‐related quality of life in Type 2 diabetes patients in the United Arab Emirates. METHODS A total of 240 Type 2 diabetes patients were recruited into a randomized, controlled, prospective clinical trial with a 12‐month follow‐up. A range of clinical measures, medication adherence and health‐related quality of life (Short Form 36) were evaluated at baseline and up to 12 months. Intervention group patients received pharmaceutical care from a clinical pharmacist, whereas control group patients received their usual care from medical and nursing staff. The primary outcome measure was change in HbA 1c. British National Formulary and Framingham scoring methods were used to estimate changes in 10‐year coronary heart disease risk scores in all patients. RESULTS A total of 234 patients completed the study. Significant reductions (P < 0.001) in mean values (baseline vs. 12 months; 95% confidence interval) of HbA 1c[8.5% (8.3, 8.7) vs. 6.9% (6.7, 7.1)], systolic [131.4 mmHg (128.1, 134.7) vs. 127.2 mmHg (124.4, 130.1)] and diastolic blood pressure [85.2 mmHg (83.5, 86.8) vs. 76.3 mmHg (74.9, 77.7)] were observed in the intervention group; no significant changes were noted in the control group. The mean Framingham risk prediction score in the intervention group was 10.56% (9.7, 11.4) at baseline; this decreased to 7.7% (6.9, 8.5) (P < 0.001) at 12 months but remained unchanged in the control group. CONCLUSIONS The pharmaceutical care programme resulted in better glycaemic control and reduced cardiovascular risk scores in Type 2 diabetes patients over a 12‐month period.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000107251.49515.c2 · Cited by 13,271
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Second Joint Task Force of European (1998) · European Heart Journal · doi:10.1053/euhj.1998.1243 · Cited by 1,131
Cranor, C. W., Bunting, B. A., & Christensen, D. B. (2003) · Journal of the American Pharmaceutical Association (1996) · doi:10.1331/108658003321480713 · Cited by 728
Effects of Exercise Training on Glucose Homeostasis
Boulé, N. G., Weisnagel, S. J., Lakka, T. A., Tremblay, A., Bergman, R. N., Rankinen, T., Leon, A. S., Skinner, J. S., Wilmore, J. H., Rao, D. C., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.1.108 · Cited by 356
Coping with Type II diabetes: the patient’s perspective
Koopmanschap, M. (2002) · Diabetologia · doi:10.1007/s00125-002-0861-2 · Cited by 158
Sell-Monitoring of Blood Glucose
(1996) · Diabetes Care · doi:10.2337/diacare.19.1.s62 · Cited by 89
Cited by
Interventions for enhancing medication adherence
Nieuwlaat, R., Wilczynski, N., Navarro, T., Hobson, N., Jeffery, R., Keepanasseril, A., Agoritsas, T., Mistry, N., Iorio, A., Jack, S., et al. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000011.pub4 · Cited by 2,945
Influence of race, ethnicity and social determinants of health on diabetes outcomes.
Walker, R. J., Strom Williams, J., & Egede, L. E. (2016) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2016.01.008 · Cited by 431
Santschi, V., Chiolero, A., Colosimo, A. L., Platt, R. W., Taffé, P., Burnier, M., Burnand, B., & Paradis, G. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.113.000718 · Cited by 349
Medication review in hospitalised patients to reduce morbidity and mortality
Christensen, M., & Lundh, A. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008986.pub3 · Cited by 298
Medication Adherence With Diabetes Medication: A Systematic Review of the Literature
Capoccia, K., Odegard, P. S., & Letassy, N. (2016) · The Diabetes Educator · doi:10.1177/0145721715619038 · Cited by 291
Metadata
- Authors
- Al Mazroui, N. R., Kamal, M. M., Ghabash, N. M., Yacout, T. A., Kole, P. L., & McElnay, J. C.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2009-04-24
- Volume
- 67
- Issue
- 5
- Pages
- 547-557
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W1977818241
- Cited by
- 175
- References
- 7
- FWCI
- 9.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Influence of pharmaceutical care on health outcomes in patients with Type 2 diabetes mellitus. https://app.cochat.ai/papers/10.1111/j.1365-2125.2009.03391.x
- The paper
- Al Mazroui, N. R., Kamal, M. M., Ghabash, N. M., Yacout, T. A., Kole, P. L., & McElnay, J. C. (2009). Influence of pharmaceutical care on health outcomes in patients with Type 2 diabetes mellitus. British Journal of Clinical Pharmacology. https://doi.org/10.1111/j.1365-2125.2009.03391.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.